top of page
%20(11_087%20x%207%20in).jpg)
NEW BOOK
LATEST NEWS
Capricor's Shares Drop After FDA Rejects Deramiocel Cell Therapy for Heart Disease in DMD
Capricor Therapeutics faced a significant setback on July 11, 2025, when the FDA rejected its cell therapy, Deramiocel , for treating...
1 day ago
FDA Rejects Ultragenyx's Gene Therapy for Rare Disease - Sanfilippo Syndrome
The FDA has declined to approve Ultragenyx Pharmaceutical's gene therapy, UX111, for treating Sanfilippo syndrome type A, a rare genetic...
1 day ago
Biogen's Salanersen Shows Promise for SMA Patients Post-Gene Therapy
Biogen’s experimental drug, Salanersen, is showing promising potential for treating children with spinal muscular atrophy (SMA), even...
Jul 1
GENE TECH TIMES
The Future Has Arrived
Capricor's Shares Drop After FDA Rejects Deramiocel Cell Therapy for Heart Disease in DMD
Capricor Therapeutics faced a significant setback on July 11, 2025, when the FDA rejected its cell therapy, Deramiocel , for treating...
1 day ago
FDA Rejects Ultragenyx's Gene Therapy for Rare Disease - Sanfilippo Syndrome
The FDA has declined to approve Ultragenyx Pharmaceutical's gene therapy, UX111, for treating Sanfilippo syndrome type A, a rare genetic...
1 day ago
Biogen's Salanersen Shows Promise for SMA Patients Post-Gene Therapy
Biogen’s experimental drug, Salanersen, is showing promising potential for treating children with spinal muscular atrophy (SMA), even...
Jul 1
Sarepta Pauses Duchenne Gene Therapy Trial After Second Patient Death
Sarepta Therapeutics has temporarily halted its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys, after a second patient died...
Jul 1
Eli Lilly Acquires Verve Therapeutics to Enhance Cardiovascular Portfolio
Eli Lilly has acquired gene-editing startup Verve Therapeutics for approximately $1 billion, expanding its portfolio to include...
Jul 1
bottom of page